Loading...
Market
What will be the outcome of Cybin's Phase 3 trial for CYB003 by end of 2025?
2
Resolution / Starting Odds
Primary endpoint met • 25%
Primary endpoint not met • 25%
Trial halted due to safety concerns • 25%
Other • 25%
Cybin's official press releases or clinical trial registries
Story
Cybin Reports 100% Response Rate, 71% Remission in Phase 2 Trial for CYB003; Stock Up 20.7%
Nov 18, 2024, 12:08 PM
Cybin Inc. has announced positive results from its Phase 2 clinical trial for CYB003, a treatment for Major Depressive Disorder (MDD). The trial revealed that 100% of participants responded to the treatment, with 71% achieving remission after just two doses of 16 mg each over a 12-month period. Following these promising results, Cybin has initiated the Phase 3 PARADIGM TM multinational pivotal program to further evaluate the efficacy and safety of CYB003. The stock price of Cybin has seen a pre-market increase of 20.7% as a result of this announcement.
View original story
Similar markets
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Study shows significant positive results • 25%
Study shows moderate positive results • 25%
Study shows no significant effect • 25%
Study shows negative results • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Positive • 25%
Negative • 25%
Inconclusive • 25%
No major trial outcome • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Yes • 50%
No • 50%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%